Author: Rectify Pharmaceuticals, Inc.

Rectify Pharmaceuticals Presents Discovery of Clinical Candidate RTY-406, a Novel Disease-Modifying Therapy for the Treatment of PSC at ACS Fall 2026 Meeting

August 27, 2026
Rectify Pharmaceuticals to Present Preclinical Data on New Dual Targeted ABCB4/BSEP Positive Functional Modulator at EASL 2026

May 13, 2026

Rectify Pharmaceuticals Presents Discovery of Clinical Candidate RTY-406, a Novel Disease-Modifying Therapy for the Treatment of PSC at ACS Fall 2026 Meeting